Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Darzalex Combination Receives Approval for First-Line Treatment of Patients with Multiple Myeloma Eligible for Transplant

Web Exclusives - FDA Updates, Multiple Myeloma, In the News

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.

This approval was based on data from the open-label, randomized, phase 3 CASSIOPEIA clinical trial, which compared induction and consolidation treatment with daratumumab plus bortezomib, thalidomide, and dexamethasone (DVTd) versus bortezomib, thalidomide, and dexamethasone (VTd) in newly diagnosed patients with multiple myeloma who were candidates for ASCT.

Results showed that the addition of daratumumab to VTd led to a 53% reduction in the risk of progression or death compared with VTd alone (hazard ratio, 0.47; 95% confidence interval, 0.33-0.67; P <.0001). The stringent complete response rate 100 days post-ASCT was 28.9% in the DVTd arm versus 20.3% in the VTd arm. At a median follow-up of 18.8 months, the median progression-free survival had not been reached in either arm.

The most common (≥20%) adverse reactions in patients who received DVTd were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral edema, neutropenia, thrombocytopenia, pyrexia, and paresthesia.

The recommended daratumumab dose is 16 mg/kg of actual body weight.

Related Items
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Synovial Sarcoma
What is Minimal Residual Disease (MRD) Negativity?
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Multiple Myeloma as a Chronic Disease
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Triplets versus Quads
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Latest Developments in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Brukinsa Receives FDA Approval for Patients with Mantle-Cell Lymphoma
TON - December 2019, Vol 12, No 6 published on December 5, 2019 in FDA Updates
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
TON - December 2019, Vol 12, No 6 published on December 5, 2019 in FDA Updates
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Web Exclusives published on December 3, 2019 in Bladder Cancer, FDA Updates, Immunotherapy
Inrebic Receives FDA Approval for Adults with Myelofibrosis
Web Exclusives published on December 2, 2019 in FDA Updates
Last modified: September 30, 2019